SMS PHARMACEUTICALS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 251.4 INR | -0.51% |
|
+2.82% | +112.26% |
| Sales 2022 | 5.2B 62.29M | Sales 2023 | 5.22B 62.55M | Capitalization | 4.93B 59.08M |
|---|---|---|---|---|---|
| Net income 2022 | 622M 7.45M | Net income 2023 | -70M -839K | EV / Sales 2022 | 1.94 x |
| Net Debt 2022 | 2.17B 25.96M | Net Debt 2023 | 2.47B 29.56M | EV / Sales 2023 | 1.42 x |
| P/E ratio 2022 |
12.7
x | P/E ratio 2023 |
-69.9
x | Employees | 1,095 |
| Yield 2022 |
0.32% | Yield 2023 |
0.52% | Free-Float | 27.61% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.36% | ||
| 1 week | +2.82% | ||
| Current month | +12.81% | ||
| 1 month | +24.31% | ||
| 3 months | +18.97% | ||
| 6 months | +91.67% | ||
| Current year | +112.26% |
1 week
241.00
265.00
1 month
201.45265.00
Current year
119.80265.00
1 year
90.80265.00
3 years
54.50265.00
5 years
23.55265.00
10 years
23.55265.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 90-08-29 | |
| Director of Finance/CFO | - | 17-09-12 | |
Tirumalesh Tumma
CMP | Compliance Officer | - | 22-02-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 90-08-29 | |
| Director/Board Member | 60 | 19-08-11 | |
| Director/Board Member | 67 | 14-08-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-09 | 251.4 | -0.51% | 27 686 |
| 24-07-08 | 252.8 | -2.71% | 17,083 |
| 24-07-05 | 259.8 | +6.19% | 114,652 |
| 24-07-04 | 244.6 | -0.43% | 8,285 |
| 24-07-03 | 245.7 | +0.31% | 21,534 |
Delayed Quote Bombay S.E., July 09, 2024 at 04:20 am EDT
More quotes
SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing of active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic, and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel, lamotrigine, penciclovir, valaciclovir, and others. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +25.13% | 44.74B | |
| +33.09% | 23.36B | |
| +24.83% | 16.24B | |
| +21.01% | 14.39B | |
| +70.05% | 13.96B | |
| -0.05% | 6.79B | |
| -13.04% | 6.4B | |
| -8.87% | 5.73B | |
| +13.36% | 5.68B |
- Stock Market
- Equities
- SMSPHARMA Stock
- SMSPHARMA Stock
